Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 23;13(11):2553. doi: 10.3390/cancers13112553

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Kaplan–Meier figures with overall survival (OS) and disease-free survival (DFS) in patients with OPSCC (A,B) and separated on subsite with TSCC/BOTSCC (C,D) and otherOPSCC (E,F). (A,B) Patients with p16 positive OPSCC had a significantly better OS and DFS compared to patients with p16 negative OPSCC (log rank: p < 0.0001 and p < 0.0001, respectively). (C,F) Patients were separated into those with cancer in lymphoepithelial sub-sites (TSCC/BOTSCC) and non-lymphoepithelial subsites (otherOPSCC) and analyzed separately. (C,D) Patients with p16 positive TSCC/BOTSCC had a significantly better OS and DFS compared to patients with p16 negative TSCC/BOTSCC (log rank: p < 0.0001 and p < 0.0001, respectively). (E,F) No significant differences in OS and DFS between patients with p16 positive and p16 negative otherOPSCC were observed (log rank: p = 0.13 and p = 0.9, respectively).

Kaplan–Meier figures with overall survival (OS) and disease-free survival (DFS) in patients with OPSCC (A,B) and separated on subsite with TSCC/BOTSCC (C,D) and otherOPSCC (E,F). (A,B) Patients with p16 positive OPSCC had a significantly better OS and DFS compared to patients with p16 negative OPSCC (log rank: p < 0.0001 and p < 0.0001, respectively). (C,F) Patients were separated into those with cancer in lymphoepithelial sub-sites (TSCC/BOTSCC) and non-lymphoepithelial subsites (otherOPSCC) and analyzed separately. (C,D) Patients with p16 positive TSCC/BOTSCC had a significantly better OS and DFS compared to patients with p16 negative TSCC/BOTSCC (log rank: p < 0.0001 and p < 0.0001, respectively). (E,F) No significant differences in OS and DFS between patients with p16 positive and p16 negative otherOPSCC were observed (log rank: p = 0.13 and p = 0.9, respectively).